Transplantation tolerance induced by mixed chimerism

Journal of Heart and Lung Transplantation

Volumn 20, Issue 8, 2001, Pages 816-823

  Wekerle, Thomas ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ANIMAL MODEL; CELLULAR IMMUNITY; CHIMERA; CLINICAL PROTOCOL; CONDITIONING; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA MATCHING; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MONKEY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RODENT; SKIN GRAFT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0034898498     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(01)00265-0     Document Type: Article

References (91)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue
3. The origin and mechanism of the allograft rejection
4. Costimulation of T lymphocytes; the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
5. A cell culture model for T lymphocyte clonal anergy
6. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
7. Transplantation tolerance with monoclonal antibodies
8. Infection breaks T cell tolerance
9. + T cells to cause immunopathology
10. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
11. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
12. Anergic T cells as suppressor cells in vitro
13. + T cell tolerance and linked suppression
14. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression
15. + regulatory cells that control intestinal inflammation
16. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
17. Anergic T cells act as suppressor cells in vitro and in vivo
18. Peripheral tolerance to class I mismatched renal allografts in miniature swine; donor antigen-activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity
19. 'Infectious' transplantation tolerance
20. Type 2 helper T cell-type cytokines and development of 'infectious' tolerance in rat cardiac allograft recipients
21. Anergic T cells effect linked suppression
22. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
23. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 activation
24. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo
25. Transfusion of polarized Th2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection
26. IL-12 antagonism induces T helper 2 responses yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimunity
27. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival?
28. Peripheral selection of the T cell repertoire
29. Extrathymic tolerance of mature T cells; clonal elimination as a consequence of immunity
30. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B
31. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
32. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
33. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade
34. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
35. A strategy for organ allografts without using immunosuppressants or irradiation
36. Clonal deletion as a mechanism of transplantation tolerance
37. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
38. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen
39. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a non-myeloablative conditioning regimen
40. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide
41. T cell tolerance by clonal elimination in the thymus
42. Selective events in T cell development
43. CD4 T cell tolerance to nuclear proteins induced by medullary thymic epithelium
44. Targeted expression of major histocompatibility complex (MHC) demonstrates that dendritic cells can induce negative but not positive selection in vivo
45. Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells
46. Distinct requirements of positive and negative selection for selecting cell type and CD8 interaction
47. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantion in mice conditioned with a non-myeloablative regimen
48. Mechanism of cotolerance in nonlethally conditioned mixed chimeras; negative selection of the Vβ T-cells receptor repertoire by both host and donor bone marrow-derived cells
49. 'Actively acquired tolerance' of foreign cells
50. Differential kinetics of various subsets of thymic bone marrow-derived stromal cells in rat chimeras
51. Differences in turnover between thymic medullary dendritic cells and a subset of cortical macrophages
52. Thymic dendritic cells
53. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
54. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
55. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen
56. Assessment of thymic output in adults after hematopoietic stem-cell transplantation and prediction of T-cell reconstitution
57. Specific tolerance induction and transplantation; a single-day protocol
58. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance
59. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model
60. Mixed chimerism without whole body irradiation in a large animal model
61. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
62. Mixed allogeneic chimerism and renal allograft tolerance in cynomologous monkeys
63. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys
64. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors
65. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation
66. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor
67. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation
68. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow
69. Mixed lymphohaemopoietic chimerism and graft-vs-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
70. Combined histocompatible leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease; the induction of allograft tolerance through mixed lymphohematopoietic chimerism
71. Immunological reconstitution of sex-linked lymphopenic immunological deficiency
72. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome
73. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-αβ monoclonal antibody, low dose irradiation, and donor bone marrow transfusion
74. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach
75. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers
76. Haematopoietic stem cells can induce specific skin graft acceptance across a full MHC barrier
77. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts
78. An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers
79. A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT
80. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody; absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
81. The combined use of sublethal irradiation and costimulatory blockade to generate mixed bone marrow chimerism
82. Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning
83. The role of T cell costimulatory activation pathways in transplant rejection
84. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
85. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand
86. + T cells, interferon-γ, and CTLA4
87. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
88. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
89. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade
90. Successful homotransplantation of the human kidney between identical twins
91. Recommendations of the expert panel on ethical issues in clinical trials of transplant tolerance